Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro.

Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ∼10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

[1]  Shieh-Yueh Yang,et al.  Hyper-high-sensitivity wash-free magnetoreduction assay on biomolecules using high- Tc superconducting quantum interference devices , 2008 .

[2]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[3]  K. Blennow,et al.  Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? , 2010, Alzheimer's Research & Therapy.

[4]  Shieh-Yueh Yang,et al.  Magnetic relaxation measurement in immunoassay using high-transition-temperature superconducting quantum interference device system , 2006 .

[5]  Shieh-Yueh Yang,et al.  Preparation and properties of superparamagnetic nanoparticles with narrow size distribution and biocompatible , 2004 .

[6]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[7]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[8]  S. Margel,et al.  Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field. , 2009, Biochemical and biophysical research communications.

[9]  T. L. Lee,et al.  Biofunctionalized magnetic nanoparticles for in vitro labeling and in vivo locating specific biomolecules , 2008 .

[10]  A. Offenhäusser,et al.  Magnetic particle detection by frequency mixing for immunoassay applications , 2007 .

[11]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[12]  Jos H Beijnen,et al.  Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. , 2008, Current clinical pharmacology.

[13]  Henrik Zetterberg,et al.  Plasma Aβ in Alzheimer's disease—up or down? , 2006, The Lancet Neurology.

[14]  I. Kloszewska,et al.  Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease. , 2007, Acta neurobiologiae experimentalis.

[15]  C. Hong,et al.  Nanomagnetic particles for SQUID-based magnetically labeled immunoassay , 2005, IEEE Transactions on Applied Superconductivity.

[16]  Lutz Trahms,et al.  Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles , 1999 .

[17]  Y. H. Lee,et al.  Dual immobilization and magnetic manipulation of magnetic nanoparticles , 2008 .

[18]  K. Blennow,et al.  Amyloid β and APP as biomarkers for Alzheimer’s disease , 2010, Experimental Gerontology.

[19]  Bengt Winblad,et al.  Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects , 2010, Experimental Gerontology.

[20]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[21]  G. Belfort,et al.  Effect of maghemite nanoparticles on insulin amyloid fibril formation: selective labeling, kinetics, and fibril removal by a magnetic field. , 2009, Journal of biomedical materials research. Part A.

[22]  N. Hamasaki,et al.  Biological Immunoassay Utilizing Magnetic Marker and High Tc Superconducting Quantum Interference Device Magnetometer , 2003 .

[23]  Robert H. Austin,et al.  Microfluidic high gradient magnetic cell separation , 2006 .

[24]  M. Irizarry.  Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.

[25]  C. Frommen,et al.  Synthesis of gadolinium oxide magnetoliposomes for magnetic resonance imaging , 2000 .